SAGE Therapeutics

SAGE Therapeutics

Sage Therapeutics is a biopharmaceutical company founded by Douglas Covey and Steven Paul in 2010 and headquartered in Cambridge, Massachusetts focused on the discovery and development of medicines to address central nervous system disorders.

Sage Therapeutics is a biopharmaceutical company headquartered in Cambridge, Massachusetts and founded in 2010 by Douglas Covey and Steven Paul. The company develops medicines and therapies to treat disorders of the central nervous system.

Funding

Series A

On October 18, 2011 Sage Therapeutics closed their series A funding round with $35 million in funding from Third Rock Ventures.

Series B

On October 16, 2013 Sage Therapeutics closed their series B funding round with $20 million in funding from Third Rock Ventures and ARCH Venture Partners.

Series C

On March 13, 2014 Sage Therapeutics closed their series C funding round with $38 million in funding from Third Rock Ventures, OrbiMed, Foresite Capital, EcoR1 Capital, and ARCH Venture Partners.

Timeline

March 2014

SAGE Therapeutics raises a $38,000,000 series C round from EcoR1 Capital, OrbiMed Advisors and Foresite Capital.

October 16, 2013

SAGE Therapeutics raises a $20,000,000 series B round from ARCH Venture Partners and Third Rock Ventures.

2010

SAGE Therapeutics was founded by Douglas Covey and Steven Paul.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Al Robichaud

Chief Scientific Officer

Amy Schacterle

Senior Vice President, Regulatory Affairs and Quality Assurance

Asha Nayak

Board Member

Deirdre Vitale

Employee

Douglas Covey

Co-Founder

Ed Christian

Employee

Erin Lanciani

Senior Vice President, people and Organizational Strategy

Geno Germano

Board Member

Heinrich Schlieker

Senior Vice President, Technical Operations

James Frates

Board Member

Jeff Jonas

CEO & Member of Board of Directors

Jeff Jonas

Board Member

Jim Doherty

Chief Research Officer

Joseph Kennedy

Employee

Kevin Star

Board Member

Kimi Iguichi

Chief Financial Officer

Meridith Unger

Employee

Michael Cola

Board Member

Mike Ackley

Employee

Mike Cloonan

Chief Business Officer

Steve Kanes

Chief Medical Officer

Steven Paul

Co-Founder & Board Member

Further reading

Title
Author
Link
Type
Date

​Five things you don’t know about Jeff Jonas, CEO of Sage Therapeutics

Don Seinffert

Web

Sage Therapeutics CEO: Have to weigh investor returns but will price postpartum drug 'fairly'

Michelle Fox

News

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
May 11, 2020
BioSpace
Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of Debra Feldman as vice president, head of regulatory
December 5, 2019
news.yahoo.com
The Cambridge-based drugmaker posted promising trial results for the key antidepressant earlier this year.
Daniel Strauss
December 5, 2019
markets.businessinsider.com
Sage Therapeutics craters 64% after failing a key trial for its depression drug

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.